CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 Trial

Trial advancing with ongoing safety and pharmacologic evaluation and planned expansion into MDS and MF

Mar. 30, 2026 at 12:51pm

Got story updates? Submit your updates here. ›

CERo Therapeutics Holdings, Inc. has dosed the second patient in the second cohort (fifth patient overall) in its Phase 1 CER-1236 clinical trial in hematologic malignancies, including acute myeloid leukemia (AML), with planned expansion into myelodysplastic syndromes (MDS) and myelofibrosis (MF). The study is progressing according to protocol, with ongoing evaluation of safety, pharmacokinetics, pharmacodynamics, and clinical activity.

Why it matters

The data generated to date support continued dose escalation and planned expansion of enrollment into patients with advanced myelodysplastic syndrome (MDS) and myelofibrosis (MF), which are patient populations with substantial unmet need. CERo is committed to continuing the clinical evaluation of CER-1236 as a potential new cell therapy approach for these diseases.

The details

The first-in-human, multi-center, open-label, Phase 1/1b study was initially designed to evaluate the safety and preliminary efficacy of CER-1236 in patients with AML that is either relapsed/refractory, or in remission with measurable residual disease, or newly diagnosed patients with TP53 mutated AML. Based on emerging safety data and clinical observations, the trial has recently been amended to include transfusion-dependent myelodysplastic syndromes (TD-MDS), high-risk MDS (HR-MDS), or post-JAK-inhibitor myelofibrosis (MF).

  • The second patient in the second cohort (fifth patient overall) has been dosed in the Phase 1 CER-1236 clinical trial.
  • The study data continue to reinforce ongoing dose escalation and planned expansion into additional patient populations.

The players

CERo Therapeutics Holdings, Inc.

An innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer.

Robert Sikorski, M.D., Ph.D.

CERo Chief Medical Officer.

Chris Ehrlich

CERo CEO.

Got photos? Submit your photos here. ›

What they’re saying

“The study is progressing according to protocol, with ongoing evaluation of safety, pharmacokinetics, pharmacodynamics, and clinical activity. The data generated to date support continued dose escalation and planned expansion of enrollment into patients with advanced myelodysplastic syndrome (MDS) and myelofibrosis (MF). These are patient populations with substantial unmet need, and we are committed to continuing the clinical evaluation of CER-1236 as a potential new cell therapy approach for patients with these diseases.”

— Robert Sikorski, M.D., Ph.D., CERo Chief Medical Officer

“CERo continues to execute the CERTAIN-T trial, with completion of the second cohort approaching. The study data continue to reinforce ongoing dose escalation and planned expansion into additional patient populations. We are grateful to the patients, investigators, study sites, and the CERo team for their contributions, and we look forward to sharing additional data as the study progresses.”

— Chris Ehrlich, CERo CEO

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

CERo's ongoing clinical trial of CER-1236 is progressing well, with plans to expand the study to include patients with myelodysplastic syndromes (MDS) and myelofibrosis (MF) in addition to acute myeloid leukemia (AML). The company remains committed to developing this novel cell therapy approach to address the substantial unmet medical needs of these patient populations.